Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)

China · Delayed Price · Currency is CNY

11.58

+0.61 (5.56%)

Jun 29, 2026, 3:04 PM CST

-23.46% (1Y)

Market Cap	12.93B -19.0%
Revenue (ttm)	2.66B -6.5%
Net Income	81.24M -52.2%
EPS	0.07 -53.8%
Shares Out	1.12B
PE Ratio	166.72
Forward PE	63.59
Dividend	0.04 (0.32%)
Ex-Dividend Date	Jun 11, 2026

Volume	23,636,799
Open	10.91
Previous Close	10.97
Day's Range	10.70 - 11.88
52-Week Range	10.79 - 21.12
Beta	0.68
Analysts	Buy
Price Target	16.44 (+41.97%)
Earnings Date	Aug 25, 2026

About SHE:300601

Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies v... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1992

Employees 1,957

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300601

Full Company Profile

Financial Performance

In 2025, SHE:300601's revenue was 2.67 billion, an increase of 0.81% compared to the previous year's 2.65 billion. Earnings were 70.33 million, a decrease of -65.12%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 300601 stock is "Buy." The 12-month stock price target is ¥16.44, which is an increase of 41.97% from the latest price.

Price Target

¥16.44

(41.97% upside)

Analyst Consensus: Buy

Stock Forecasts